Analysis of the risk factors of radiation pneumonitis and the predictive ability of dosiomics in non-small-cell lung cancer

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Higgins KA, Puri S, Gray JE. Systemic and radiation therapy approaches for locally advanced non–small-cell lung cancer. J. Clin. Oncol. 40(6), 576–585 (2022).
  Medline CASGoogle Scholar
• 2. Antonia SJ, Villegas A, Daniel D et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 377(20), 1919–1929 (2017).
  Medline CASGoogle Scholar
• 3. Shintani T, Kishi N, Matsuo Y et al. Incidence and risk factors of symptomatic radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent chemoradiotherapy and consolidation durvalumab. Clin. Lung Cancer 22(5), 401–410 (2021).
  Medline CASGoogle Scholar
• 4. Palma DA, Senan S, Tsujino K et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int. J. Radiat. Oncol. Biol. Phys. 85(2), 444–50 (2013). • This article provides reliable historical data on curative chemoradiotherapy for non-small-cell lung cancer (NSCLC).
  MedlineGoogle Scholar
• 5. Ren W, Liang B, Sun C et al. Dosiomics-based prediction of radiation-induced hypothyroidism in nasopharyngeal carcinoma patients. Phys. Med. 89, 219–225 (2021).
  MedlineGoogle Scholar
• 6. Liang B, Yan H, Tian Y et al. Dosiomics: extracting 3D spatial features from dose distribution to predict incidence of radiation pneumonitis. Front. Oncol. 9, 269 (2019).
  MedlineGoogle Scholar
• 7. Rossi L, Bijman R, Schillemans W et al. Texture analysis of 3D dose distributions for predictive modelling of toxicity rates in radiotherapy. Radiother. Oncol. 129(3), 548–553 (2018).
  MedlineGoogle Scholar
• 8. van Griethuysen JJM, Fedorov A, Parmar C et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 77(21), e104–e107 (2017).
  Medline CASGoogle Scholar
• 9. Dossun C, Niederst C, Noel G, Meyer P. Evaluation of DIR algorithm performance in real patients for radiotherapy treatments: a systematic review of operator-dependent strategies. Phys. Med. 101, 137–157 (2022).
  Medline CASGoogle Scholar
• 10. Weichselbaum RR, Liang H, Deng L, Fu Y-X. Radiotherapy and immunotherapy: a beneficial liaison? Nat. Rev. Clin. Oncol. 14(6), 365–379 (2017).
  Medline CASGoogle Scholar
• 11. McLaughlin M, Patin EC, Pedersen M et al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat. Rev. Cancer 20(4), 203–217 (2020).
  Medline CASGoogle Scholar
• 12. Fiorica F, Belluomini L, Stefanelli A et al. Immune checkpoint inhibitor nivolumab and radiotherapy in pretreated lung cancer patients: efficacy and safety of combination. Am. J. Clin. Oncol. 41(11), 1101–1105 (2018).
  Medline CASGoogle Scholar
• 13. Ratnayake G, Shanker M, Roberts K et al. Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer. Asia Pac. J. Clin. Oncol. 16(1), 56–62 (2020).
  MedlineGoogle Scholar
• 14. Bestvina CM, Pointer KB, Karrison T et al. A phase 1 trial of concurrent or sequential ipilimumab, nivolumab, and stereotactic body radiotherapy in patients with stage IV NSCLC study. J. Thorac. Oncol. 17(1), 130–140 (2022).
  Medline CASGoogle Scholar
• 15. Theelen WSME, Peulen HMU, Lalezari F et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 5(9), 1276–1282 (2019). • Clearly reports the conclusion: immune checkpoint inhibitors combined with radiotherapy will increase the incidence of radiation pneumonitis (RP) in NSCLC patients.
  MedlineGoogle Scholar
• 16. Shaverdian N, Lisberg AE, Bornazyan K et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 18(7), 895–903 (2017).
  Medline CASGoogle Scholar
• 17. Li M, Gan L, Song A, Xue J, Lu Y. Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy. Biochim. Biophys. Acta Rev. Cancer 1871(2), 323–330 (2019). •• This meta-analysis provides important conclusions: biomarkers, clinical factors and dosimetric factors can be used to predict the occurrence of RP, which is crucial for effective management.
  Medline CASGoogle Scholar
• 18. Geng Y, Zhang Q, Feng S et al. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Cancer Med. 10(4), 1222 (2021). •• Radiobiological studies have shown that traditional dosimetry indicators cannot fully describe the radioactive response of tissues, whereas dosiomics features contain rich information, such as shape and texture, for three-dimensional dose-distribution prediction.
  Medline CASGoogle Scholar
• 19. Placidi L, Cusumano D, Lenkowicz J, Boldrini L, Valentini V. On dose cube pixel spacing pre-processing for features extraction stability in dosiomic studies. Phys. Med. 90, 108–114 (2021).
  Medline CASGoogle Scholar
• 20. Buizza G, Paganelli C, D'Ippolito E et al. Radiomics and dosiomics for predicting local control after carbon-ion radiotherapy in skull-base chordoma. Cancers (Basel). 13(2), 339 (2021).
  Medline CASGoogle Scholar
• 21. Qin Y, Zhu L-H, Zhao W, Wang J-J, Wang H. Review of radiomics- and dosiomics-based predicting models for rectal cancer. Front. Oncol. 12, DOI: 10.3389/fonc.2022.913683 (2022). •• In the field of thoracic oncology, studies have demonstrated that models combining radiological features with dosimetric parameters are superior to models with radiological features alone.
  Google Scholar
• 22. Jin X, Zheng X, Chen D et al. Prediction of response after chemoradiation for esophageal cancer using a combination of dosimetry and CT radiomics. Eur Radiol 29(11), 6080–6088 (2019).
  MedlineGoogle Scholar
• 23. Bi J, Qian J, Yang D et al. Dosimetric risk factors for acute radiation pneumonitis in patients with prior receipt of immune checkpoint inhibitors. Front. Immunol. 12, 828858 (2022).
  MedlineGoogle Scholar
• 24. Lee SH, Han P, Hales RK et al. Multi-view radiomics and dosiomics analysis with machine learning for predicting acute-phase weight loss in lung cancer patients treated with radiotherapy. Phys. Med. Biol. 65(19), DOI: 10.1088/1361-6560/ab8531 (2020).
  Google Scholar
• 25. Ren W, Liang B, Sun C et al. Dosiomics-based prediction of radiation-induced hypothyroidism in nasopharyngeal carcinoma patients. Phys. Med. 89, 219–225 (2021).
  MedlineGoogle Scholar